FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
15 letters match. Newest first.
-
BiologicsStephen J. Fallon, Ph.D.
FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.
High risk -
DrugsJose M. Carpio, M.D.
FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.
Medium -
BiologicsAdnan Dahdul, MD
FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.
High risk -
DevicesExThera Medical Corporation
ExThera shipped Seraph 100 blood filters for compassionate use without FDA approval and promoted them as approved.
High risk -
DevicesUnited Health Products, Inc.
FDA warns United Health Products over unapproved significant-risk study of CelluSTAT absorbable hemostat and trial oversight failures.
High risk -
DrugsArmstrong County Memorial Hospital
FDA warns Armstrong County Memorial Hospital review board over missing procedures and inadequate meeting minutes for drug research.
Medium -
DrugsLouisiana State University Health Science Center IRB
FDA warns Louisiana State University Health Science Center IRB about missed continuing reviews and unreported study terminations for drug research.
Medium -
BiologicsMassachusetts Institute of Technology MIT
FDA says MIT's review board for human research failed to make sure consent forms and meeting records met federal rules.
Medium -
DrugsNew York State Psychiatric Institute IRB
FDA warned New York State Psychiatric Institute's review board it failed to report serious research problems and reviewed drug studies without required nonscientific member.
High risk -
DevicesNobles Medical Technology II, Inc.
FDA warns Nobles Medical Technology II over oversight failures in NobleStitch EL clinical study.
High risk -
DrugsJeffrey W. Taub, M.D./Children's Hospital of Michigan
FDA warns Detroit investigator over pediatric drug trial protocol deviations and lapsed IRB approval.
High risk -
DrugsLarkin Community Hospital Institutional Review Board
Larkin Community Hospital IRB cited for approving trials without required nonscientist member and incomplete records.
Medium -
DrugsDaniel Fred Goodman, M.D./Goodman Eye Center
FDA warns Dr. Daniel Fred Goodman/Goodman Eye Center over clinical drug study without required FDA application and missing consent/assent.
High risk -
DrugsSabine S. Hazan, M.D.
FDA warned Dr. Sabine Hazan that she enrolled and gave investigational drugs to subjects while IRB (ethics board) approval had lapsed.
High risk -
DrugsKDunn and Associates, P.A. dba HealthQuilt
Houston research sponsor ran a COVID-19 drug study on people without an FDA-approved application or proper consent forms.
High risk